key: cord-1008389-hfjdncxd
authors: Welch, N. L.; Zhu, M.; Hau, C.; Weller, J.; Ezzaty Mirhashemi, M.; Mantena, S.; Nguyen, T. G.; Shaw, B.; Ackerman, C. M.; Thakku, S. G.; Tse, M. W.; Kehe, J.; Bauer, M. R.; Uwera, M.-M.; Eversley, J. S.; Bielawski, D. A.; McGrath, G.; Braidt, J.; Johnson, J.; Cerrato, F.; Petros, B. A.; Gionet, G. L.; Jalbert, S. K.; Cleary, M. L.; Siddle, K. J.; Happi, C. T.; Hung, D. T.; Springer, M.; MacInnis, B.; Lemieux, J.; Rosenberg, E. S.; Branda, J. A.; Blainey, P. C.; Sabeti, P.; Myhrvold, C.
title: Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and SARS-CoV-2 variants
date: 2021-12-15
journal: nan
DOI: 10.1101/2021.12.14.21267689
sha: a387c27f52fa36c36f8d521bb6738453f2e05899
doc_id: 1008389
cord_uid: hfjdncxd

The COVID-19 pandemic has demonstrated a clear need for high-throughput, multiplexed, and sensitive assays for detecting SARS-CoV-2 and other respiratory viruses as well as their emerging variants. Here, we present microfluidic CARMEN (mCARMEN), a cost-effective virus and variant detection platform that combines CRISPR-based diagnostics and microfluidics with a streamlined workflow for clinical use. We developed the mCARMEN respiratory virus panel (RVP) and demonstrated its diagnostic-grade performance on 533 patient specimens in an academic setting and then 166 specimens in a clinical setting. We further developed a panel to distinguish 6 SARS-CoV-2 variant lineages, including Delta and Omicron, and evaluated it on 106 patient specimens, with near-perfect concordance to sequencing-based variant classification. Lastly, we implemented a combined Cas13 and Cas12 approach that enables quantitative measurement of viral copies in samples. mCARMEN enables high-throughput surveillance of multiple viruses and variants simultaneously.

and eliminates the color-coding and dropletization needs of CARMEN v1 by using 139 commercially available integrated fluidic circuits (IFCs) on the Fluidigm Biomark 38 140 (Fluidigm, San Francisco, CA) (Fig. 1a) . By leveraging Fluidigm microfluidics, we 141 overcame the need for a custom microscope and chips as well as data analysis 142 expertise, which were required for CARMEN v1. The Fluidigm IFCs use a specific 143 number of assay combinations: 192 samples by 24 detection assays or 96 samples by 144 96 detection assays which are all spatially separated. After manual IFC loading, the 145

Fluidigm controller moves the samples and detection assays through individual 146 channels on the IFC until they reach the chip reaction chamber, where they are 147 thoroughly mixed. We measure fluorescence on the Fluidigm Biomark with our custom 148 automated protocols that take images of the IFC chip every 5 minutes for 1-3 hours at 149 37°C (Extended Data Fig. 1a ). 150 151

In our first implementation of the mCARMEN platform, we designed a panel to detect 21 152 clinically relevant human respiratory viruses (Supp. Table 2 ). This includes all viruses 153 covered by BioFire RP2.1 -SARS-CoV-2, four other human-associated coronaviruses 154

and both influenza strains -as well as a few additional illness inducing viruses 39 . To 155 generate maximally active virus-specific crRNAs and PCR primers to detect the 21 156

viruses, we applied the assay design method ADAPT (Activity-informed Design with All-157

inclusive Patrolling of Targets; described in methods) 35 . We were able to encompass 158 the full genomic diversity of these viral families by including multiple primers, if needed. 159 160 We compared the performance of mCARMEN to CARMEN v1 for detecting synthetic 161 DNA fragments recapitulating the 21 viral targets, and found mCARMEN had the same 162 (13 viruses) or better (8 viruses) analytical sensitivity compared with CARMEN v1 (Fig.  163 1b and 1c, Extended Data Fig. 1b) . Both mCARMEN and CARMEN v1 had 100% 164 analytical specificity, but mCARMEN was 100% sensitive to 10 2 copies/μL and 98.4% 165 sensitive to 10 1 copies/μl while CARMEN v1 was only 86% and 77.8% sensitive, 166

respectively. Moreover, the mCARMEN reaction rate is accelerated compared with 167 CARMEN v1, resulting in faster initial detection and signal saturation of targets (Fig. 1d,  168 Extended Data Fig. 1c ). This is likely due to the higher temperature at reaction initiation 169 for mCARMEN (37°C) than for CARMEN v1 (25°C), and the extensive sample-detection 170 assay mixing that occurs in the mCARMEN IFC, rather than merged droplets mixing by 171 diffusion in CARMEN v1. 172 173 We then benchmarked the performance of both CARMEN diagnostics against RT-174 qPCR 40 and/or unbiased metagenomic NGS on patient specimens. We obtained a set 175 of 6 SARS-CoV-2-positive, 4 SARS-CoV-2-negative, and 8 influenza A virus (FLUAV)-176 positive patient specimens for initial testing. mCARMEN and CARMEN v1 had 100% 177 concordance with RT-qPCR, NGS, and each other (Fig. 1e) . We also compared 178 performance using two different fluorescent reporters, RNase Alert (IDT, Coralville, IA) 179

and a custom 6-Uracil-FAM (polyU) reporter 34 . We found enhanced sensitivity when 180 using a polyU fluorescent reporter due to LwaCas13a's preference to cleave at 181 uracils 28,29 (Extended Data Fig. 2a&b ).

Aside from SARS-CoV-2 and influenza viruses, the remaining 19 viruses detectable by 184 mCARMEN lack a recognized gold-standard clinical diagnostic. Thus, we compared 185 mCARMEN to unbiased metagenomic NGS results for the characterization of 58 pre-186 pandemic unknown samples collected from patients with a presumed upper respiratory 187 infection (Fig. 1f , Supp. Table 3 , Extended Data Fig. 2c&d ). Both mCARMEN and NGS 188 detected the same respiratory viruses in 12 specimens (7 FLUAV, 2 HCoV-229E, 1 189

HCoV-NL63, 1 HCoV-OC43, and 1 HMPV), neither detected respiratory viruses in 42 190 specimens, and they had differing results for 4 specimens, with 93% overall 191 concordance based on an average of ~3 million reads per specimen. Nine of the 12 192 specimens positive by both methods assembled complete genomes while the remaining 193

3 assembled partial or no genomes but had >10 reads (2 FLUAV, 1 HMPV). With a drive towards clinical applications, we aimed to optimize the mCARMEN 204

workflow. To do so, we decreased the manual labor and processing time from >8 hours 205 to <5 hours by implementing automated RNA extraction, using a single-step RNA-to-206

DNA amplification with 1 primer pool, and reducing the duration of detection readout 207 (Fig. 2a, Extended Data Fig. 3a) . We then preliminarily evaluated the optimized 208 workflow on 21 SARS-CoV-2 positive and 8 negative patient specimens, and found 209 greater sensitivity over the original two-step amplification method (Extended Data Fig.  210 3b).

For an end-to-end mCARMEN workflow, we developed software to be used alongside 213 clinical testing to provide patient diagnoses (Extended Data Fig. 6 ). The software uses 214 the final image at 1 hour post-reaction initiation as input, then automatically validates 215 controls to make 1 of 3 calls: "detected," "not detected," or "invalid" for each combination 216 of sample and crRNA.

Lastly, we wanted to condense mCARMEN for focused clinical use and did so by 219 developing a respiratory virus panel (RVP) to detect 9 of the most clinically-relevant 220 viruses (SARS-CoV-2, HCoV-HKU1, HCoV-OC43, HCoV-NL63, FLUAV, FLUBV, HPIV-221 3, HRSV, and HMPV) and a human internal control, (RNase P). These nine viruses 222

were included on RVP based on if they heavily circulate in the population and have 223 capacity to cause respiratory virus symptoms, while others were excluded if genomic 224 diversity was difficult to account for concisely, such as HRV 42 . We first conducted range-225 determining limit of detection (LOD) studies for the 9 viruses on mCARMEN RVP in a 226

research laboratory. The preliminary LOD was within the range of 100-1,000 copies/mL 227 for SARS-CoV-2, FLUAV, FLUBV, HCoV-HKU1, HCoV-NL63, HCoV-OC42, and 1,000-228 20,000 copies/mL for HPIV-3, HMPV, HRSV (Extended Data Figure 5a , Supp. Table 4) , 229 with robust performance from the SARS-CoV-2 crRNA as well as all RVP crRNAs in 230 combination (median AUCs of 1 and 0.989, respectively) (Extended Data Figure 5b -g). 231 232

To benchmark mCARMEN RVP performance to comparator assay results, we analyzed 233 390 SARS-CoV-2-positive and 143 negative patient specimens, and compared these 234 results to both prior and concurrent RT-qPCR evaluation (Fig. 2c ). By the time of 235 comparative evaluation the number of RT-qPCR positive specimens dropped from 390 236

to 317, suggesting significant sample degradation either from extended sample storage 237 or multiple freeze-thaw cycles. Nonetheless, mCARMEN was able to identify all 317 238 (100% sensitivity) of the concurrent RT-qPCR positive specimens. We noted, 239 mCARMEN further detected SARS-CoV-2 in 44 specimens that tested positive by prior 240

RT-qPCR, but were missed by concurrent RT-qPCR testing, suggesting mCARMEN is 241 more robust to sample quality issues. Indeed, if we categorize putative true positives as 242

all specimens that tested positive by prior RT-qPCR as well as present-day RT-qPCR 243

and/or mCARMEN, mCARMEN would have 100% sensitivity compared to 88% for qPCR. mCARMEN also detected SARS-CoV-2 in 3 specimens that tested negative by 245

both prior and concurrent RT-qPCR (Fig. 2e ). While we cannot rule out the possibility of 246 false-positives, several pieces of evidence suggest they are more likely to be true 247 positives: mCARMEN demonstrates higher sensitivity over concurrent RT-qPCR testing, 248 these specimens are from suspected SARS-CoV-2 cases based on clinical features, 249

and mCARMEN did not detect SARS-CoV-2 in any clinical specimens prior to the 250 pandemic ( Fig. 1 Table  273 3). Fifteen out of the 16 true negatives had no more than 2 reads mapped to the SARS-274

CoV-2 genome, in line with <10 reads expected for negative specimens, while 1 275 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint RT-qPCR are more sensitive.

Evaluation of RVP performance in a clinical setting 297 298

We implemented mCARMEN RVP in the CLIA-certified Clinical Microbiology Laboratory 299

at Massachusetts General Hospital (MGH) to establish assay sensitivity and specificity 300

for clinical validation following FDA guidelines 43 . We first evaluated the limit of detection 301

(LOD), defined as the lowest concentration yielding positive results for at least 19 of 20 302

replicates. After recapitulating the 9 viral targets on RVP, we found the LOD for HCoV-303 HKU1, HCoV-NL63, HCoV-OC43, FLUAV, and FLUBV were 500 copies/mL while 304 HMPV and SARS-CoV-2 were 1,000 copies/mL, and HPIV-3 and HRSV were 10,000 305 copies/mL (Fig. 3a&b , Extended Data Fig. 7a ). The LOD likely varies between viral 306

targets for a few reasons: the crRNAs have varying activity levels on their intended 307 target and differing input materials were used based on sample availability. 308 309

After establishing the single analyte LODs, we asked whether co-infections impacted 310 the sensitivity for each virus detected by RVP. To do so, we added SARS-CoV-2 at a 311 constant, 2x LOD, concentration to the remaining 8 viruses on RVP at varying 312 concentrations at or above their respective LOD (Extended Data Fig. 7b ). We observed 313 no loss in our ability to detect SARS-CoV-2. However, we noticed a decrease in signal 314

intensity for the other viruses at lower concentrations, yet only one virus, HPIV-3, had a 315 10-fold higher LOD.

Although we observed no cross-reactivity between RVP panel members in the research 318 setting ( Fig. 1 and 2), we followed FDA guidelines to conduct more stringent assay 319 inclusivity and specificity analyses against common respiratory flora and other viral 320

pathogens. In silico analysis revealed the primers on RVP are >92% inclusive of the 321 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.14.21267689 doi: medRxiv preprint known genetic diversity of each viral species, with additional inclusivity coming from 322 crRNA-target recognition, for an overall >95% inclusivity (Supp . Table 5 ). When 323 examining off-target activity in silico, FDA defines cross-reactivity as >80% homology 324 between one of the primers or probes to any microorganism. We found no more than 325 75% homology between the RVP primer and crRNA sequences to other closely related 326

human pathogens (Supp. Table 6 ). This implies that off-target detection will rarely, if 327 ever, occur. 328 329

Following in silico analysis, we evaluated RVP specificity experimentally. We 330 computationally designed position-matched synthetic gene fragments from closely 331 related viral species, including both human-and non-human-infecting species. When 332 evaluating these gene fragments, only SARS-CoV-2 and RaTG13 showed cross-333 reactivity (Fig. 3c, Extended Data Fig. 8) . This cross-reactivity is expected, however, 334

because the RaTG13 amplicon evaluated shares 100% nucleotide identity with the 335 SARS-CoV-2 amplicon in our assay. We did not observe any cross-reactivity when 336

using viral seed stocks, genomic RNA, or synthetic RNA from ATCC or BEI (Supp. 337 Table 7 ). Therefore, we found RVP to have 100% analytical specificity.

Finally CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.14.21267689 doi: medRxiv preprint HRSV) and mCARMEN did not detect virus in 6 specimens (1 FLUAV, 1 FLUBV, 1 368 HRSV, and 3 HMPV). Both mCARMEN and BioFire identified 5 specimens with co-369

infections (HCoV-NL63 in a FLUAV specimen, HPIV-3 in a FLUBV specimen, HCoV-370 HKU-1 in 2 HRSV specimens, and HCoV-NL63 in a HRSV specimen). Together with 371 the original clinically detected co-infection, there were 6 (1.1%) co-infections in our 372 specimen set (Extended Data Fig. 7c ). Overall, mCARMEN and BioFire were 99.4% 373

(1485/1494 individual tests) concordant (Fig. 3e , Extended Data Fig. 9 ). For the 374 contrived samples, mCARMEN correctly identified 99% (148/150) (Fig. 3e) .

We used unbiased metagenomic NGS to further evaluate 9 discordant specimens (2 377 FLUAV, 2 FLUBV, 2 HRSV, and 3 HMPV), generating an average of 13 million reads 378 per specimen. Either no viral reads were present by NGS or partial genomes were 379

assembled, but the RVP amplicon was missing, making it unlikely for our assay to 380 return a positive result (Extended Data Fig. 9 , Supp. With the continuous emergence of mutations that can lead to increased transmissibility 399 or enhanced virulence, we also wanted to greatly streamline assay generation for each 400 new SARS-CoV-2 mutation or variant. Thus, we developed an easily adaptable method 401

to track these changes that we call the mCARMEN variant identification panel (VIP).

VIP has two non-overlapping primer pair sets within conserved regions of the spike 403 gene to amplify the full-length sequence for use with any crRNA pair. These 26 crRNA 404 pairs, individually or in combination, allow us to track existing variants as well as identify 405

emerging variants, such as Omicron (Fig. 4a ). Initially, we tested over 60 combinations 406 of crRNAs on unamplified synthetic material to identify the crRNA pairs with the largest 407 fluorescence ratio for expected divided by unexpected signal at each mutation 408

(Extended Data Fig. 10 ).

We validated the flexible VIP method by testing RNA extracted from SARS-CoV-2 viral 411 seed stocks, for the ancestral (Washington isolate: USA-WA1, ATCC) lineage, and 412

Alpha, Beta, Gamma, Delta, and Epsilon lineages (Fig. 4b , Extended Data Fig. 11 ). As 413 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint crRNA has different kinetics owing to varying hit-calling thresholds, we almost always 417 observed a higher expected signal above the unexpected signal, which is important in 418 the prevention of false positive results (Extended Data Fig. 12 ). 419 420

For clinical relevance, we developed an automated variant calling procedure that 421 evaluates the mutation-specific signal in SARS-CoV-2-positive patient specimens and 422 returns a variant lineage result (Extended Data Fig. 13a , described in methods). For 423 some mutations at the same or similar genomic position we observed cross-reactive 424 signals which we overcame by comparing the maximum fluorescent ratios between 425 those mutations and assigning the positive call to the higher of the two (Extended Data 426 Fig. 13b ).

We applied VIP and the analysis pipeline to identify the variant lineage in 106 known 429 SARS-CoV-2-positive patient specimens: 24 Alpha, 23 Beta, 24 Gamma, 6 Delta, and 430

24 Epsilon, and 5 presumptive Omicron specimens. Of the 101 specimens with NGS 431 results, excluding Omicron specimens, all but 3 (97%) specimens (1 Beta and 2 432

Gammas) were given the correct variant lineage identification (Fig. 4c&d , Extended 433

Data Fig. 13c , Supp. Similar to widely-used multiplexed approaches, like BioFire 17 , the original design of 458 CARMEN 37 did not provide a true quantitative assessment of viral genome copies 459 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.14.21267689 doi: medRxiv preprint present in a sample. Establishing the total viral quantity in a patient is important for 460 assessing the stage of infection, transmission risk, and most effective treatment plan 9,10 . 461

The gold standard assay for sample quantification, RT-qPCR, leverages the standard 462 curve -serial dilutions of a given target at a known concentration -as a means of using 463

Ct values to approximate viral quantity 44 . We wanted to determine if a similar approach 464 could be applied to mCARMEN.

To make mCARMEN quantitative, we took advantage of the existence of multiple 467 CRISPR/Cas proteins with differing reaction kinetics and enzymatic activities, and the 3 468 fluorescent channels detected by the Fluidigm Biomark (Fig. 5a) . We incorporated DNA-469

targeting CRISPR/Cas12 into the Cas13 reaction, and used protein-specific reporters in 470 different fluorescent channels, HEX and FAM, respectively to maximize our multiplexing 471

capabilities. To capture reaction kinetics, images of the IFC chip are taken every 5 472 minutes for 3 hours to generate sigmoidal curves from the fluorescent signals over time.

When considering enzymatic activities, Cas13 has enhanced sensitivity compared to 474

Cas12 since the process of reverse transcribing the dsDNA sample input for Cas13 475 detection results in increased starting concentration. Thus, we use Cas12 to capture the 476 kinetic curves of higher copy material on the standard curve and Cas13 to capture lower 477 copy material.

We integrated our quantification efforts into RVP, since this assay was extensively 480 evaluated in both research and clinical settings. We manually designed Cas12 crRNAs 481

in the same region of the viral genome that the RVP Cas13 crRNAs target for a two-482

step standard curve generation on the same target amplicon for Cas12-and Cas13-483

RNPs individually. The first step requires plotting the fluorescence for a range of 484 concentrations (Cas12: 10 7 -10 3 copies/μL; Cas13: 10 3 -10 0 copies/μL) at each time point 485

to calculate the IC50 through a sigmoidal, four parameter logistic (4PL) curve, R 2 >0.9 486 (Fig. 5b , Extended Data Fig. 14a&b ). In some cases, we could not determine the IC50 487 value because signal saturation occurred too quickly or not at all and therefore, that 488 concentration was excluded from analysis. In the second step, we plotted the IC50 values 489 onto a semilog line, where concentration is logarithmic and time is linear, to generate 490 the standard curves ( Fig. 5c ). We compared these results to a standard curve 491 generated from RT-qPCR using the same serial dilutions and found a linear relationship 492

between SARS-CoV-2 and FLUAV IC50 values to Ct values (R 2 0.901 and 0.881, 493 respectively) (Fig. 5d ). In all, these results suggest that by using Cas12 and Cas13 in 494 combination, we could extrapolate viral quantification -spanning a 10 0 -10 6 range of 495 target concentrations -from patient specimens with performance similar to RT-qPCR. 496 497

Here, we report mCARMEN, a high-throughput, multiplexed, and microfluidic diagnostic 500 and surveillance platform with panels for respiratory viruses and SARS-CoV-2 variants 501 that can be parallelized to test 300-550 patient specimens in an 8 hour working day. To 502 make mCARMEN a clinically relevant technology, we built on CARMEN v1 37 by 503 streamlining the workflow and incorporating commercially available Fluidigm 504 instrumentation 38 . We validated mCARMEN on 902 patient specimens for the detection 505 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.14.21267689 doi: medRxiv preprint of 9-21 human respiratory viruses (RVP) or SARS-CoV-2 variant mutations (VIP) with 506 high concordance to comparator assays which passed the FDA's performance criteria 43 507 for all but one virus. Notably, when testing previously positive clinical specimens, we 508

found a substantial proportion were not positive by concurrent testing, but were positive 509 by mCARMEN (Fig. 2 ). This suggests sample degradation issues -a known problem 510

when detecting RNA viruses in clinical specimens 41,45 -that mCARMEN is more robust to 511

handling than RT-qPCR or NGS. Though we cannot rule out false positives, we did not 512 detect SARS-CoV-2 in specimens prior to the pandemic and we had 100% concordance 513

with true virus-negative specimens. 514 515

To enhance mCARMEN's clinical diagnostic relevance and meld it with surveillance 516

technology requirements, we further maximized its multiplexing capabilities by 517 discriminating between mutations for variant lineage classification in patient specimens 518

and quantifying viral genomic copies. Currently, variant lineage classification is only 519 evaluated by NGS, which is costly and relies on specialized expertise found outside the 520 clinic 22,24 . VIP gives similarly rich information about key SARS-CoV-2 mutations at 5-10x 521 cheaper, per sample, than NGS, and is far more comprehensive than current nucleic 522

acid-based diagnostics. Importantly, VIP was poised to differentiate Omicron 523

immediately as it emerged since we routinely design guides to preemptively identify 524 mutations of interest in the spike gene in preparation for emerging variants. Given the 525 number of mutations detected by VIP, we expect to observe distinct mutation signatures 526 between variant lineages that will allow us to differentiate these and future variants of 527 concern from each other without assay redesign. We also adapted mCARMEN for dual 528

Cas12 and Cas13 detection by capitalizing on the differing protein kinetics. A few 529 groups have studied Cas12 and Cas13 reaction kinetics to inform assay 530 quantification 46,47 , but the range of concentrations being quantified has been limited due 531

to reaction saturation. We expanded the quantifiable concentration range to 5-6 orders 532 of magnitude, which is similar to RT-qPCR. These mCARMEN applications have the 533 potential to provide a more holistic diagnosis to the patient. 534 535

We rapidly developed mCARMEN for use in the pandemic, but faced challenges during 536

the clinical validation and approval process needed for a large-scale roll-out. 537

Specifically, it was difficult to obtain at least 30 previously confirmed clinical specimens 538

for each virus on RVP with enough material available for extensive concurrent testing, 539

while also facing specimen degradation issues that inevitably occur over time. 540 mCARMEN's performance exceeded FDA requirements, yet the FDA was unable to 541

give it full emergency use authorization (EUA) review and approval because of their 542 limited bandwidth and need to prioritize other applications. Lastly, funding to support 543 mCARMEN in clinics and beyond has been scarce despite there being a clear need for 544

it.

Although further work would be required to bring mCARMEN fully to the clinic, 547 mCARMEN can function as an ideal single technology platform with diagnostic and 548

surveillance capabilities for detecting respiratory pathogens and variants. We have 549 taken significant steps to streamline assay workflow while enhancing sensitivity and not 550 sacrificing specificity. There is currently no other diagnostic technology that combines 551 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.14.21267689 doi: medRxiv preprint multiplexed pathogen testing with variant tracking and is highly scalable and amenable 552

to clinical laboratory settings. This technology has the potential to test for other 553

infectious diseases 48 and sample types for an even more comprehensive, multiplexed, 554

and high-throughput diagnostic, all while maintaining a level of clinical relevance that is 555

unmatched to other nucleic acid-or antigen-based diagnostics. 556 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Heatmap showing mCARMEN fluorescent data across 21 human respiratory viruses 560 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.14.21267689 doi: medRxiv preprint that were amplified using two separate primer pools. Synthetic DNA fragments were 561 serially diluted from 10 3 -10 1 copies/μL and added to Q5 amplification master mix. All 562 samples were background subtracted from NTC-noMg negative control. c, 563

Concordance between CARMEN v1 and mCARMEN from b. Blue: targets at 10 3 564 copies/μL; green: targets at 10 2 copies/μL; red: targets at 10 1 copies/μL. d, 565

Fluorescence kinetics of amplified SARS-CoV-2 DNA gene fragments from 10 4 -10 1 566

copies/μL at 0, 60, and 180 minutes post-reaction initiation. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. target LOD at multiple concentrations, 5,000, 2,500, 1,000, and 500 copies/mL for 20 623

replicates. c, Normalized fluorescence for each virus on RVP evaluated against on-624 target sequence, closely related sequences (Supp. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. fastest is plotted as either ancestral/mutation (blue, negative) or mutation/ancestral 639 (purple, positive). * indicates the particular mutation was confirmed by NGS. c, 640

Comparison The Corporation, and holds equity in the companies.

Code availability 752

The code used for data analysis in this study is made available on Github: 753 https://github.com/broadinstitute/mcarmen.

Data availability 756

All requests for raw and analyzed data and materials will be reviewed by the Broad 757

Institute of Harvard and MIT to verify if the request is subject to any intellectual property 758 or confidentiality obligations. Data and materials that can be shared will be released via 759

a Material Transfer Agreement. RNA sequencing data will be made available upon 760 request for academic use and within the limitations of the provided informed consent by 761 the corresponding author upon acceptance. Source code is available on github: 762 https://github.com/broadinstitute/mcarmen. 763 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint We followed the CARMEN v1 platform for two-step reverse transcription amplification 817 then transitioned to a single-step amplification reaction after experiments depicted in 818 Figure 1 . We used the Qiagen OneStep RT-PCR Mix for Figures 2,3 We plotted reference-normalized background-subtracted fluorescence for guide-target 862

pairs. For a guide-target pair (at a given time point, t, and target concentration), we first 863 computed the reference-normalized value as (median(Pt-P0)/(Rt-R0)) where Pt is the 864 guide signal (FAM) at the time point, P0 is its background measurement before the 865 reaction, Rt is the reference signal (ROX) at the time point, R0 is its background 866 measurement, and the median is taken across replicates. We performed the same 867 calculation for the no template (NTC) control of the guide, providing a background 868 fluorescence value for the guide at t (when there were multiple technical replicates of 869 such controls, we took the mean value across them). The reference-normalized 870

background-subtracted fluorescence for a guide-target pair is the difference between 871

these two values. NS-1' algorithm was used. These aligned sequences were then fed into ADAPT for 883 crRNA design with high coverage using the 'minimize guides' objective (>90% of 884 sequences detected). Once highly conserved regions of the viral genome were selected 885

with ADAPT for optimal guide design, primers were manually designed to amplify a 100-886 250 bp target region with the crRNA predicted to bind in the middle of the fragment.

ADAPT's constraints on primer specificity were relaxed and in some cases multiple 888

primers were needed to encompass the full genomic diversity of a particular virus 889 species. For optimal amplification, the primers were split into two pools. These primer 890 pools and crRNA sequences are listed in Supp. Table 2 . 891 892

3aii. Target control -PIC1 and PIC2 893

The consensus sequences generated directly above after multiple genome alignment 894

with MAFFT were used to order a 500 bp dsDNA fragment encompassing the primer 895

and crRNA binding sites. RNA was generated following the method described in 896

'General mCARMEN Procedure -Preparation of IVT Material' and diluted to 10 6 897 copies/μl in pools based on the primer pools mentioned above (PIC1, PIC2). The PICs 898

were used as input into the CARMEN v1 or mCARMEN detection reaction to function as 899 a detection positive control. 900 901 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint We followed the data analysis pipeline from CARMEN v1 to demultiplex and readout the 960 fluorescence intensity of the reporter channel for each droplet reaction performed (REF 961

CARMEN v1). In brief, pre-merge imaging data was processed using custom Python 962 scripts to detect fluorescently-encoded droplets in microwells and identify their inputs 963

based on their fluorescence intensity in three encoding channels, 647 nm, 594 nm, and 964 555 nm. Subsequently, post-merge imaging data was analyzed to extract the reporter 965 signal of the assay in the 488 nm channel, and those reporter fluorescence intensities 966

were physically mapped to the contents of each microwell. Quality control filtering was 967 performed based on the appropriate size of a merged droplet from two input droplets 968 and the closeness of a droplet's color code to its assigned color code cluster centroid. 969

The median and standard error were extracted from the replicates of all assay 970 combinations generated on the array. 971 972

3eii. mCARMEN 973 We followed the methods under 'General CARMEN Procedures -Fluidigm Data 974

Analysis' and further visualized the data using python, R, and Prism. 975 976 4. Single-step amplification troubleshooting. 977

The following RT-PCR kits were tested to determine the best performing assay: (1) 978

OneStep All or a combination of the following thermal cycling condition ranges were tested to 986

shorten assay run-time: reverse-transcription at 50 °C at 15-30 min, PCR activation at 987 95 °C at 5-15 min, denaturation step at 94 °C at 10-30 s, and extension step at 72 °C for 988 10 s to 1 min. The final extension at 72 °C for 10 min was omitted in all runs. The 989

following primer pool conditions were also tested to optimize the assay: 150 nM, 300 990 nM, 500 nM, and 600 nM of virus-specific primer and 100 nM and 150 nM of RNaseP 991 primers, with 5 μM of each virus-specific primer and 1.7 μM of RNaseP primers. 992

Reaction volumes tested include: 20 μl with 10% RNA template input, 30 μl with 20% 993 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint 

The TaqPath™ 1-Step Multiplex Master Mix Kit (Thermo Fisher) was used to amplify 999 nucleic acid according to the manufacturer's instructions, using custom primer pools in 1000 20 μl reactions. Primer pools of 150 nM, 300 nM, and 500 nM and anneal temperatures 1001 of 58 °C and 60 °C and were all tested and compared to determine optimal conditions. 1002

The following thermal cycling conditions were used: (1) Fig. 2)  1029 5a. Design of 9-virus respiratory panel and RNase P 1030

We designed this panel according to the methods described above under 'Respiratory 1031

Panel -Design' for these 9 viruses: SARS-CoV-2, HCoV-HKU1, HCoV-OC43, HCoV-1032 NL63, FLUAV, FLUAV-g4, FLUBV, HPIV-3, HRSV, and HMPV, with the addition of an 1033

RNase P primer pair and crRNA. RNase P primers and crRNAs were designed within 1034 the same region of the gene as the CDC RT-qPCR assay (Supp. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.14.21267689 doi: medRxiv preprint All patient specimens evaluated on RVP were additionally evaluated concurrently with 1038 the CDC 2019-nCoV Real-Time RT-PCR Diagnostic Panel for N1 and RNase P. A 1039 subset of specimens were selected for further study using Next Generation Sequencing.

Of the 533 patient specimens evaluated only two specimens had no detectable levels of 1042

RNase P above threshold, one of which was positive for SARS-CoV-2 while the other 1043

was virus-negative. The RNase P negative, but virus-positive, specimen likely has a 1044 high concentration of viral RNA, which sequesters amplification materials during the 1045 reaction, limiting RNase P amplification. The double negative specimen suggests 1046

possible extraction failure or sample integrity issues and was thus excluded from further 1047 analysis. with spike-in of RNA template (SARS-CoV-2 and RNaseP) to make a ten-fold serial 1070 dilution from 10 0 to 10 6 copies/μL. This was run on the QuantStudio™ 1071 6 Flex System. 1072 1073

5eiii. Next Generation Sequencing 1074

Metagenomic sequencing libraries were generated as previously described 6,50 . Briefly, 1075

extracted RNA was DNase treated to remove residual DNA then human rRNA was 1076 depleted. cDNA was synthesized using random hexamer primers. Sequencing libraries 1077

were prepared with Illumina Nextera XT DNA library kit and sequence with 100-1078 nucleotide or 150-nucleotide paired-end reads. Data analysis was conducted on the 1079

Terra platform (app.terra.bio); all workflows are publicly available on the Dockstore Tool 1080

Registry Service. Samples were demultiplexed using demux_plus to filter out known 1081 sequencing contaminants. SARS-CoV-2 genomes were assembled using 1082 assemble_refbased, all other viral genomes were assemble_denovo and additionally 1083 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.14.21267689 doi: medRxiv preprint visualized using classify_kraken, geneious, and R. A virus was determined to be 1084 present if more than 10 reads mapped to a particular viral genome. Full genomes were 1085 deposited into GenBank (Accession # here). 1086 1087

6. Clinical Evaluation of RVP in CLIA-certified laboratory at MGH (Fig. 3)  1088 6a.RVP preparation 1089 1090

6ai. Design 1091

We designed this panel according to the methods described above under 'RVP Testing 1092

at Broad -Design'. Sample and assay mixtures can be prepared in advance for multiple 96-sample batches 1120

following similar methods, with the following changes: the batch sample mix contained 1121 all reagents described above, excluding 9 mM MgCl2, and the batch assay mix 1122 contained all reagents described above, excluding 2x Assay Loading Reagent. Both 1123 mixtures were calculated with 10% overage. Both mixtures were stored at −80 °C until 1124 use. 9 mM MgCl2 was added to the sample mix and 2x Assay Loading Reagent was 1125 added to each assay mix before use. 1126 1127 6aiv. SYBR RT-qPCR of viral seed stock and genomic RNA from ATCC and BEI 1128

Resources 1129 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.14.21267689 doi: medRxiv preprint Quantification of all viral seed stock and genomic RNA received from ATCC and BEI 1130 resources was performed using the Power SYBR Green RNA-to-Ct 1-Step Kit 1131

(ThermoFisher). Reactions were run in triplicate with 1 μL RNA input in 10 μL reactions.

A primer mix at 500nM was used, and all primer sequences used are listed in Supp. 1133 Standard curves were made with spike-in of RNA template to make a ten-fold serial 1137 dilution from 10 0 to 10 6 copies/μL. This was run on the QuantStudio™ 6 Flex System. use.

A preliminary LOD for each assay was determined by testing triplicates of RNA purified 1168 using the extraction method described in 'RVP panel'. The approximate LOD was 1169 identified by extraction, amplification, and detection of 10-fold serial dilutions of IVT 1170

RNA of known titer (copies/µL) for 5 replicates. These concentrations ranged from 1e4-1171

1e-3 copies/μL. The lower bound of the LOD range was determined as the lowest 1172 concentration where 5/5 replicates were positive, and the upper bound was determined 1173

as the concentration 10-fold above the lower bound. A confirmation of the LOD for each 1174 assay was determined by testing 20 replicates of RNA, purified using the extraction 1175 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint either the respective assay or specimens is turned invalid. All patients specimens to be 1317 valid need to be either positive for RNase P or at least one other assay. Finally, the 1318 software annotates the results as csv files and visualizes them as an annotated 1319

heatmap. 1320 1321 7. Variant Testing (Fig. 4)  1322 7a. Design 1323

The crRNAs for SNP discrimination were designed using a generative sequence design 1324 algorithm (manuscript in prep.). This approach uses ADAPT's predictive model to 1325

predict the activity of candidate crRNA sequences against on-target and off-target 1326 sequences 35 . These predictions of candidate crRNA activity steer the generative 1327

algorithm's optimization process, in which it seeks to design crRNA probes that have 1328 maximal predicted on-target activity and minimal predicted off-target activity. Using this 1329 design algorithm, we selected the 26 mutations to detect and discriminate between the 1330 variants (Supp. To determine if an ancestral or derived sequence is present, the signals between 1345 respective ancestral and derived crRNA pairs must be evaluated and compared (Supp. 1346 Table 2 ). First, background subtracted reporter fluorescence is normalized to the 1347 background subtracted passive reference dye (ROX) fluorescence for each assay in the 1348 IFC. Next, the ancestral:derived and derived:ancestral ratios are calculated for each five 1349 minute-interval time point across 180 minutes. For each crRNA pair, the ratio reaching a 1350 crRNA pair-specific threshold at the earliest time point is selected. If the 1351 ancestral:derived ratio is selected, then the sequence present is determined to be 1352

ancestral. If the derived:ancestral ratio is selected, then the sequence present is 1353 determined to contain the mutation targeted by the derived crRNA within the SARS-1354

CoV-2 spike gene. crRNA pair-specific thresholds were determined based on ancestral 1355

and variant control samples, also referred to as the seedstock samples, tested in 1356 parallel with the unknown samples. For a given crRNA pair, the threshold was set to the 1357 lowest value with the maximum combined sensitivity and specificity when applied to the 1358 seedstock samples. For crRNA's detecting a SNP at the same position, the second 1359 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint 2) At least one unique crRNA specific to a single SARS-CoV-2 variant must be 1370 above the fluorescence ratio threshold. If there is not one unique crRNA signal 1371 above threshold, a result of "Variant Not Identified" will be returned. 1372

3) If two or more mutations for a given variant fall below the threshold, a result of 1373 "Variant Not Identified" will be returned. All other mutations must surpass the 1374 threshold. 1375 4) If three or more unexpected mutations for a given variant are above threshold, a 1376 result of "Variant Not Identified" will be returned. At most, two unexpected signals 1377

can occur as long as parameters 1 and 2 are met.

If all three parameters are met, the result of "Variant Identified" will be returned. If the 1380 parameters are not met, a result of "Variant Not Identified" will be returned. Samples 1381 that contain additional derived signals that fall outside of the typical variant lineage 1382 mutation list follow the below parameters. If 1-2 unexpected signals are observed 1383

slightly above threshold yet all other signals are correct for a specific variant lineage 1384 then the unexpected signal will be disregarded and the variant call will be made on the 1385 remaining signals. If more than two unexpected signals are observed above threshold 1386

and either all other signals are correct for a specific variant lineage or are not perfectly 1387 matching a result of "Variant Uncertain" will be returned. 1388 1389 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.14.21267689 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CARMEN v1 values are shown as raw fluorescence (red) while signal using the polyU 1601

reporter is shown directly above signal using RNase Alert (Thermo initiation. 58 patient specimens were extracted using the KingFisher Flex MagMAX 1609 mirVana kit then amplified in 2 steps with 2 separate primer pools. c, Amplification from 1610 primer pool 1 d, amplification from primer pool 2. All specimens were background 1611 subtracted using NTC-amp as a negative control. Asterisks (*) represent specimens 1612 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.14.21267689 doi: medRxiv preprint with known infections by unbiased NGS, more than 10 reads mapped to the viral 1613 genome .  1614  1615  1616  1617  1618  1619  1620  1621  1622  1623  1624  1625  1626  1627  1628  1629  1630  1631  1632  1633  1634  1635  1636  1637 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Prior RT-qPCR results shown as expected infection positive (+) or negative (-). All 1645 specimens were background subtracted using NTC-amp as a negative control. Asterisk 1646 (*) represent differences between one-step and two-step amplification results. 1647 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.14.21267689 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. represents signal that is either unexpected or expected for the given variant lineage 1840

based on NGS results. 1841 1842 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint Target SARS-CoV-2 copies/mL 10,000,000 1,000,000 100,000 10,000 1,000 100 10 1

Positive/total 5/5 5/5 5/5 5/5 3/5 0/5 0/5 0/5 Target HCoV-HKU1 copies/mL 10,000,000 1,000,000 100,000 10,000 1,000 100 10 1

Positive/total 5/5 5/5 5/5 4/5 2/5 0/5 0/5 0/5 Target HCoV-NL63 copies/mL 10,000,000 1,000,000 100,000 10,000 1,000 100 10 1

Positive/total 5/5 5/5 5/5 5/5 5/5 3/5 0/5 0/5 Target HCoV-OC43 copies/mL 10,000,000 1,000,000 100,000 10,000 1,000 100 10 1

Positive/total 5/5 5/5 5/5 4/5 2/5 2/5 0/5 0/5 Target FLUAV copies/mL 10,000,000 1,000,000 100,000 10,000 1,000 100 10 1

Positive/total 5/5 5/5 5/5 3/5 2/5 0/5 0/5 0/5 Target FLUBV copies/mL 10,000,000 1,000,000 100,000 10,000 1,000 100 10 1

Positive/total 5/5 5/5 5/5 5/5 5/5 1/5 0/5 0/5 Target HPIV-3 copies/mL 10,000,000 1,000,000 100,000 10,000 1,000 100 10 1 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.14.21267689 doi: medRxiv preprint Positive/total 5/5 5/5 5/5 5/5 5/5 1/5 0/5 0/5 Target HRSV copies/mL 10,000,000 1,000,000 100,000 10,000 1,000 100 10 1

Positive/total 5/5 5/5 5/5 5/5 3/5 0/5 1/5 0/5 Target HMPV copies/mL 10,000,000 1,000,000 100,000 10,000 1,000 100 10 1

Positive/total 5/5 5/5 5/5 4/5 1/5 0/5 0/5 0/5 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint

The copyright holder for this this version posted December 15, 2021. ; https://doi.org/10.1101/2021.12.14.21267689 doi: medRxiv preprint

1391 1392 There are a few exceptions worth mentioning: we observed crRNAs for SNPs E484Q, 1393 P681R, N501T, and L452Q, had undesirable cross-reactive signals with a position 1394 matched or adjacent mutation, and were, thus, excluded from further evaluation. 1395 1396 8. Cas13-and Cas12-based detection with mCARMEN

COVID-19 testing: One size does not fit all

SARS-CoV-2 transmission without symptoms

Negative Nasopharyngeal and Oropharyngeal Swabs Do Not 1429 Rule Out COVID-19

False Negative Tests for SARS-CoV-2 1431 Infection -Challenges and Implications

Phylogenetic analysis of SARS-CoV-2 in Boston highlights the 1433 impact of superspreading events

SARS-CoV-2 variants, spike mutations and immune escape

Tracking SARS-CoV-2 variants

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected 1439 Patients

Virological assessment of hospitalized patients with COVID-2019

Multiplex qPCR discriminates variants of concern to enhance 1443 global surveillance of SARS-CoV-2

Multiplexed, quantitative serological profiling of COVID-19 1445 from blood by a point-of-care test

Performance Characteristics of a High-Throughput Automated 1447 Transcription-Mediated Amplification Test for SARS-CoV-2 Detection

TaqPath TM COVID-19 Combo Kit

CDC's Influenza SARS-CoV-2 Multiplex Assay and Required Supplies

Xpert Xpress SARS-CoV-2/Flu/RSV

Evaluation of the BioFire® COVID-19 test and Respiratory Panel 1456 2.1 for rapid identification of SARS-CoV-2 in nasopharyngeal swab samples

SARS-CoV-2 Assay Test from ChromaCode

Robust Multichannel Encoding for Highly Multiplexed Quantitative 1461 PCR

SARS-CoV-2 Variants of Interest and Concern naming scheme 1463 conducive for global discourse

In Vitro Diagnostics EUAs -Molecular 1465 Diagnostic Tests for SARS-CoV-2

Understanding variants of SARS-CoV-2

Tracking SARS-CoV-2 lineage B.1.1.7 dissemination: insights from 1471 nationwide spike gene target failure (SGTF) and spike gene late detection (SGTL) 1472 data

Next-generation sequencing in the 1474 clinic: promises and challenges

Clinical and biological insights from viral 1476 genome sequencing

Metagenomic Analysis Reveals Clinical SARS-CoV-2 Infection and 1478 Bacterial or Viral Superinfection and Colonization

Global disparities in SARS-CoV-2 genomic surveillance

C2c2 is a single-component programmable RNA-guided 1482 RNA-targeting CRISPR effector

Nucleic acid detection with CRISPR-Cas13a/C2c2

Noncanonical crRNAs derived from host transcripts enable 1486 multiplexable RNA detection by Cas9

Field-deployable viral diagnostics using CRISPR-Cas13

CRISPR-Cas12a target binding unleashes indiscriminate single-1490 stranded DNase activity

CRISPR-Cas12a-assisted nucleic acid detection

Streamlined inactivation, amplification, and Cas13-based 1494 detection of SARS-CoV-2

36. Joung, J. et al. Detection of SARS-CoV-2 with SHERLOCK One-Pot Testing

Massively multiplexed nucleic acid detection with Cas13

Human Respiratory Viruses☆

TaqPath TM COVID-19 Combo Kit

Stability of 1507 viral RNA in clinical specimens for viral diagnosis

Sequencing and analyses of all known human rhinovirus 1510 genomes reveal structure and evolution

Office of the Commissioner. Emergency Use Authorization

Real-time PCR in virology. Nucleic Acids 1515 Res

The impact of viral transport media on PCR assay 1517 results for the detection of nucleic acid from SARS-CoV-2

Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a 1520 and mobile phone microscopy

Kinetic analysis of Cas12a and Cas13a RNA-Guided nucleases 1522 for development of improved CRISPR-Based diagnostics

Multiplexed detection of bacterial nucleic acids using Cas13 in 1525 droplet microarrays

MAFFT Multiple Sequence Alignment Software Version 1528 7: Improvements in Performance and Usability

All 1668 samples were background subtracted using NTC-amp as a negative control. Plus sign 1669 (+) represent negative sample call by mCARMEN results. b&e, Area under the receiver 1670 operating characteristic (AUROC) curve for crRNA detection. Blue bar represents the 1671 maximal AUROC time point at 60 minutes post-reaction initiation c&f, Evaluation of 1672 sensitivity and specificity of crRNA detection to establish hit calling threshold. Black line: 1673 sensitivity/true positive rate; gray line: specificity/true negative rate; red line: hit calling 1674 threshold. d&g, Confusion matrix of expected vs predicted detection. b-d, SARS-CoV-2 1675 crRNA detection only. e-g, all nine respiratory viruses on RVP. 1676 1677 1678 Extended Data Figure 6. SARS-CoV-2 clinical specimen testing in an academic 1679 setting at the Broad. a, Average normalized fluorescence for SARS-CoV-2 across 8-1680 14 patient specimens within Ct ranges of 15

Scatter plot of mean Ct of 1684 one or two technical replicates compared to mCARMEN scaled normalized 1685 fluorescence. c, Scatter plot of RNase P scaled normalized fluorescence from Fig. 1b 1686 compared to RNase P Ct values obtained from concurrent RT-qPCR testing of 533 1687 patient specimens. Green: positive RNase P signal detected by both RVP and RT-1688 qPCR; gray: inconclusive RT-qPCR result indicating one or two of the three technical 1689 replicates were undetermined; black: undetermined RT-qPCR result indicating all three 1690 technical replicates were negative for SARS-CoV-2. d, RNase P RT-qPCR inconclusive 1691 specimens from c. Scatter plot of mean Ct of one or two technical replicates compared 1692 to mCARMEN scaled normalized fluorescence. Green: positive detection by both RVP 1693 and RT-qPCR; purple: RVP positive; gray: RT-qPCR positive; black: negative by both 1694 RVP and RT-qPCR

Scaled normalized fluorescence values at 1 hr are 1704 shown for SARS-CoV-2 and RNase P, as well as another RVP virus. SARS-CoV-2 viral 1705 seed stock was spiked into pooled negative specimen at 2,000 copies/mL (2x the LOD 1706 established in Fig. 3b). Additionally, viral seed stock, isolated RNA extracted from 1707 clinical specimens, or synthetic RNA was additionally spiked at 10 7 -10 3 copies/mL. Error 1708 bars, one standard deviation from the median fluorescence. Blue: RVP virus at varying 1709 concentrations; light purple: SARS-CoV-2; black: RNase P from negative patient 1710 specimen. c, Concordance between RVP and Biofire RP 2.01/2.1 for 6 patient 1711 specimens with co-infections visualized as a split heatmap. Purple: RVP and BioFire 1712 2.0/2.1 positive; blue: RVP virus-positive; green: Biofire RP2.0/2.1 virus-positive; white: 1713 virus-negative. 1714 1715 1716 1717 1718 1719 1720 1721 1722 1723 1724 contrived samples to RVP. Contrived samples were prepared by spiking viral seed 1745 stock, genomic RNA, or synthetic RNA into negative patient specimen

Gamma: 10 4 -10 2 copies/μL, and Delta: 10 3 -10 1 copies/μL. Purple: variant lineage

Shaded regions 1794 represent 95% confidence intervals around the median fluorescence values and lines 1795 specificity

Cas13 (blue) and Cas12 (orange) for 5 or 7 concentrations, respectively, up to 120 min

sequences, FFT-NS-ix1000 was used. For viral species with >1000 sequences, FFT-1912 NS-1 was used for the MAFFT alignment. The primer and crRNA sequences were then 1913 mapped to the aligned viral sequences using a consensus alignment to determine 1914 percent identity (homology). The average homology was taken across the panel 1915 sequences and the total number of sequences evaluated. Bolded text represents on-1916 target primers/crRNA to the intended viral sequences. Not all sequence combinations 1917 were evaluated since whole genome homology between many viruses is significantly 1918 less than 80%. None of the primer or crRNA sequences has >80% homology to other, 1919 unintended viral or bacterial sequences, making the panel highly specific to the 1920 particular viruses of interest. More specifically

Streptococcus pneumoniae, Streptococcus pyogenes, Bordetella pertussis, 1926 Mycoplasma pneumoniae, Pneumocystis jirovecii, Candida albicans, Pseudomonas 1927 aeruginosa, Staphylococcus epidermis, Streptococcus salivarius

Design of targets for specificity. 1183 In silico analysis -Inclusivity 1184Inclusivity was tested by performing an in silico analysis using all publicly available 1185 sequences of all targets on the RVP panel. Complete genomes for all viruses were 1186 downloaded from NCBI on April 2, 2021 and aligned using MAFFT v7. For viral species 1187with less than 1000 sequences, the FFT-NS-ix1000 algorithm was used to create the 1188MAFFT alignment. For viral species with >1000 sequences, the FFT-NS-1 algorithm 1189 was used to create the MAFFT alignment. The primer and crRNA sequences were then 1190 mapped to the aligned viral sequences using a consensus alignment to determine the 1191 percent identity (homology) and the number of mismatches. The average homology and 1192 mismatches were taken across the total number of sequences evaluated. Please note 1193 that mismatches below for crRNA sequences do not take wobble base pairing (G-U 1194 pairing) into account. Results are summarized in Supp. HRSV.

The results were automatically displayed on the FilmArray software with each target in a 1290 run reported as "detected" or "not detected." If either control fails, the software marks 1291 this run as "invalid." When sufficient human sample volume was available, samples with 1292invalid results were re-run. 1293 12946e. Analysis Software 1295The analysis software comprises python scripts executing the data analysis described in 1296Methods 2h and taking into account the controls described in Methods section 6aii. 1297They are packaged into an executable with graphical user-interface using the Python 1298 module Gooey 1.0.7. 1299 1300In short, the reference-normalized background-subtracted fluorescence is calculated for Dynamic range = | mean of positive controls -mean of negative controls| 1307 1308If the ratio of separation band to dynamic range is equal or less than 0.2, the whole assy 1309 is invalid. Next, for the positive and negative controls, outliers based on three standard 1310 deviations are identified. If a positive control has a too low value or a negative control a 1311 too high value, the respective assay is invalid. For the remaining samples, hit calling is 1312 performed based on comparing the signal to the water control. If the signal is 1.8x 1313 8a. Design for Cas12-based detection 1398Cas13 crRNAs from RVP were utilized. Cas12 crRNAs were manually designed in the 1399 same region of the viral genome as the Cas13 crRNAs to reduce the need for additional 1400 primer design while maintaining Cas12's PAM requirements. Only one additional primer 1401was designed inorder to properly amplify all targets on RVP. All crRNAs and primers are 1402 listed in Supp. Table 2 . 8c. Data analysis 1412We generally followed the methods under 'General mCARMEN Procedures -Analysis' 1413 this time with also taking into account VIC signal separate from FAM signal. We used a 1414 custom python script to determine whether the FAM signal of a reaction is significantly 1415 above background by comparing it to the no-template control. If the background-1416subtracted and normalized fluorescence intensity is 1.8 higher than the normalized and 1417background-subtracted no-templated control, the assay is considered positive. 1418 1419 1420 1421Citations 1422 Supplementary